Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — Investor Presentation (April 2022)
17 slides from Genetic Signatures's investor presentation, April 2022
Slide 1: Investor Presentation April 2022
Investor Presentation April 2022
Slide 2: Disclaimer
Investor DOCUMENT Presentation TITLE Disclaimer SEPTEMBER April 2022 2021 This presentation has been prepared by Genetic Signatures Limited ACN 095 913 205 (the Company or GSS) and approved by the Board of Directors for release. It comprises written materials/slides for a verbal presentation concern
Slide 3: Company Summary
Company Summary InvestorTITLE DOCUMENT Presentation SEPTEMBER 2021April 2022 Established ASX listed developer and manufacturer of molecular (PCR) based test kits for infectious diseases Novel 3base® technology – changes DNA sequence, detects the most common mutations, rapid, low cost and accurate Ea
Slide 4: EasyScreen Detection Kits
Trusted & Proven Technology Investor DOCUMENT Presentation SEPTEMBER TITLE April 2022 2021 A ‘Syndromic Screening’ approach allows users to test a broad range of clinically relevant pathogens based on patient symptoms, helping clinicians make an accurate diagnosis EasyScreen™ Detection Kits Simultan
Slide 5: Novel proprietary technology: 3base platform
Novel proprietary technology: Investor Presentation April 2022 proprietary 3base® platform technology underpins the EasyScreenTM product range Our proprietary 3base® solution… …improves workflow and increases throughput EasyScreen™ kits are compatible with most 1 3base® platform technology converts
Slide 6: 3base Technology: less sequence variation
3base® Technology: less sequence variation Investor Presentation April 2022 • Reduced sequence variation • Improved subtype similarity • No cross-reaction with 4- base native sequences, reduced laboratory contamination • 3base® greatly simplifies the multiplexing process • Simple Multiplex Primer/Pr
Slide 7: Financial Summary – Sales
Investor DOCUMENT Presentation TITLE Financial Summary – Sales SEPTEMBER April 2022 2021 Revenue from sales (A$m) Continued Strong Revenue Growth 30.6 3Q FY22 $8.7m, up 108% on pcp; increased 28.3 contribution from overseas 8.7 SARS-CoV-2 test demand tapering, being replaced 5.4 with other tests 4.2
Slide 8: Financial Summary – Cashflow
Investor DOCUMENT Presentation TITLE Financial Summary – Cashflow SEPTEMBER April 2022 2021 A'000s 3Q FY22 YTD FY22 Planned use of funds Receipts from customers 11,834 34,258 Instrument development - $10-12m Payments to suppliers and employees (9,750) (24,187) Future US FDA clearances ‒ 3+ products
Slide 9: Financial Summary – 1H FY22 Profit & Loss
Investor DOCUMENT Presentation TITLE Financial Summary – 1H FY22 Profit & Loss SEPTEMBER April 2022 2021 A'000s 1H FY22 1H FY21 Profitable while growing business Sales revenue 21,838 18,693 17% increase in 1H sales over pcp Cost of materials & freight (6,890) (6,086) Gross margin improved 1% to 68.4
Slide 10: EasyScreen Detection Kit Range
Investor DOCUMENT Presentation TITLE EasyScreenTM Detection Kit Range SEPTEMBER April 2022 2021 Registrations Current In process Enteric * Detects 20+ gastroenteritis pathogens including Salmonella, Giardia and Norovirus Respiratory US EUA Detects 14 common respiratory infections including Influenza
Slide 11: Instruments
Investor DOCUMENT Presentation TITLE Instruments SEPTEMBER April 2022 2021 GS-1000 GS-Mini • Fully automated cartridge design • Higher throughput platform • Rapid extraction of DNA & RNA (188 samples per run) • Reduce wastage/costs; choice of • Onboard sample & reagent 1 to 12 samples traceability •
Slide 12: Enteric Product Range - Protozoan, Viral and Bacterial
Investor DOCUMENT Presentation TITLE Enteric Product Range - Protozoan, Viral and Bacterial SEPTEMBER April 2022 2021 Product Summary EasyScreen™ enteric testing kits allow for flexible syndromic testing of over 20 clinically relevant pathogenic microorganisms Improved diagnostics allows for earlier
Slide 13: Enteric Protozoan Product – Road to FDA 510(k)
Investor DOCUMENT Presentation TITLE Enteric Protozoan Product – Road to FDA 510(k) SEPTEMBER April 2022 2021 Process Clinical trials Prepare FDA File with FDA Clearance submission •3 sites, min 2 in USA •Analysis of discrepants, •Timeframe 90 days for •1,500 samples DNA sequencing of response •Mark
Slide 14: Milestones
Investor DOCUMENT Presentation TITLE Milestones SEPTEMBER April 2022 2021 Enteric Protozoa Public FDA 2-year extension option Health application Wales 3-year Option to contract extend PHW Expansion in Europe contract Leveraging COVID-19 momentum to expand customer base 2022 2023 2024 2025 3+ new Eas
Slide 15: Next Steps – Beyond COVID
Next Steps – Beyond COVID Investor DOCUMENT Presentation SEPTEMBER TITLE April 2022 2021 Leverage COVID-19 – new customers, new tests Continue building interest in EasyScreenTM kits in US & EU markets using expanded sales teams and SARS-CoV-2 experience as leverage SARS-CoV-2 only customers have fiv
Slide 16: Reasons to Invest
Reasons to Invest Investor DOCUMENT Presentation SEPTEMBER TITLE April 2022 2021 Attractive investment proposition • Business model with Continued product expansion favourable unit economics • 5 product groups in • Increasing international development recognition via EasyScreenTM Significant market
Slide 17: Contact us
Contact us Dr John Melki Peter Manley Genetic Signatures Ltd Genetic Signatures Ltd Chief Executive Officer Chief Financial Officer E: john.melki@geneticsignatures.com E: peter.manley@geneticsignatures.com P: +61 (0)2 9870 7580 Visit us www.geneticsignatures.com Follow us 17
Genetic Signatures — Investor Presentation (April 2022) on 6ix